We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Gearing up T-cell immunotherapy in cervical cancer.
Current Problems in Cancer 2018 March
The World Health Organization estimates more than 270,000 deaths annually by cervical cancer. Present vaccines are prophylactic in nature which cannot treat huge bulk of cervical cancer patients worldwide. Available therapies like radiotherapy, chemotherapy, or surgery are not effective in high-grade lesion, and hence, there is an unmet medical need for an effective form of therapy. T cells play a significant role in cervical cancer pathogenesis as human papilloma virus uses multiple mechanisms that dodge host T-cell immune-surveillance aiding in persistence of infection and establishment of cancer. Therefore, T-cell-based immunotherapy is gaining momentum since it is more specific and is entitled with broader therapeutic potential. This review outlines various ongoing research and trials in field of T-cell immunotherapy for treating cervical cancer using different fundamental strategies. It is becoming an important pharmacological tool and therapeutic option against cervical disease, as more and more studies are extending from preclinical studies to human trials.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app